Walleye Trading’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-245,900
Closed -$170K 5705
2020
Q4
$170K Buy
245,900
+71,434
+41% +$152K ﹤0.01% 3636
2020
Q3
$393K Buy
174,466
+29,000
+20% +$82.8K ﹤0.01% 2458
2020
Q2
$521K Sell
145,466
-173,500
-54% -$626K ﹤0.01% 2258
2020
Q1
$1.21M Sell
318,966
-231,886
-42% -$764K 0.01% 1171
2019
Q4
$1.66M Buy
+550,852
New +$1.43M 0.01% 1365

Other funds holding BMY.RT

Walleye Trading's BMY.RT Position: Q1 2021 in Review

Walleye Trading sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 245,900 shares — an estimated $170K sold.

Walleye Trading first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.66M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Walleye Trading reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Walleye Trading sold 245,900 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $170K.
  • Walleye Trading first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Walleye Trading's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.66M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Walleye Trading's 13F filing for Q1 2021, filed 17 May 2021.